How should I transition a patient from an unfractionated heparin infusion to apixaban?

Transitioning from Heparin Infusion to Apixaban

Stop the heparin infusion and start apixaban at the time of the next scheduled heparin dose without any overlap or bridging period. 1

Transition Protocol

The FDA-approved approach for switching from parenteral anticoagulants (including unfractionated heparin) to apixaban is straightforward:

• Discontinue the heparin infusion
• Begin apixaban at the usual time the next heparin dose would have been administered 1
• No bridging or overlap is required

Apixaban Dosing Based on Indication

The specific apixaban regimen depends on your clinical indication:

For Acute VTE Treatment (DVT/PE)

• Initial 7 days: 10 mg orally twice daily
• After 7 days: 5 mg orally twice daily 2, 1

For Atrial Fibrillation

• Standard dose: 5 mg orally twice daily
• Reduced dose (2.5 mg twice daily) if patient has ≥2 of the following:
  • Age ≥80 years
  • Body weight ≤60 kg
  • Serum creatinine ≥1.5 mg/dL 1

For VTE Secondary Prevention (after ≥6 months of treatment)

• 2.5 mg orally twice daily 2, 1

Key Clinical Considerations

Unlike dabigatran and edoxaban, apixaban does NOT require a minimum duration of parenteral anticoagulation before initiation. This is a critical distinction—dabigatran and edoxaban require 5-10 days of parenteral therapy before starting, but apixaban has a built-in loading dose regimen that allows direct transition 2.

Important Caveats

Hemodynamically unstable PE: Do not use apixaban as an alternative to unfractionated heparin for initial treatment of patients with PE who present with hemodynamic instability or who may require thrombolysis or pulmonary embolectomy 1. Continue heparin in these cases.

Triple-positive antiphospholipid syndrome: Avoid apixaban in patients who are triple positive (lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies) due to increased thrombotic risk compared to warfarin 1.

Renal dysfunction: In patients with acute kidney injury, consider monitoring drug-specific anti-Xa levels if available to guide timing of transition, though this is not standard practice 3. The pharmacodynamic effect of apixaban persists for at least 24 hours (approximately two half-lives) 1.

Practical Implementation

1. Timing: Stop heparin and give the first apixaban dose at the time the next heparin dose would be due
2. No gap needed: The transition is seamless without waiting periods
3. No monitoring required: Unlike warfarin transitions, no INR or aPTT monitoring is needed during the switch 1
4. Patient counseling: Ensure the patient understands the twice-daily dosing requirement and the importance of adherence to prevent thrombotic events 1

The simplicity of this transition—compared to the complex bridging required with warfarin—represents a significant practical advantage of apixaban in clinical practice.